285 related articles for article (PubMed ID: 21458316)
1. Prostate-specific antigen (PSA) should drive doing prostate biopsies.
Loeb S; Catalona WJ
Urol Oncol; 2012; 30(1):1-2. PubMed ID: 21458316
[No Abstract] [Full Text] [Related]
2. [Prostatic specific antigen in practice in 1997].
Salomon L; Colombel M; Patard JJ; Chopin D; Abbou CC
Ann Urol (Paris); 1998; 32(2):69-72. PubMed ID: 9599634
[TBL] [Abstract][Full Text] [Related]
3. Is the PSA test useless?
Kirby R; Moul JW
Prostate Cancer Prostatic Dis; 2004; 7(4):271-2. PubMed ID: 15592438
[No Abstract] [Full Text] [Related]
4. Significance of serum free prostate specific antigen in the screening of prostate cancer.
Higashihara E; Nutahara K; Kojima M; Okegawa T; Miura I; Miyata A; Kato M; Sugisaki H; Tomaru T
J Urol; 1996 Dec; 156(6):1964-8. PubMed ID: 8911366
[TBL] [Abstract][Full Text] [Related]
5. PSA screening.
Cohen S; Schiff S; Kelty P
Med Health R I; 2005 Mar; 88(3):90-1. PubMed ID: 15915782
[No Abstract] [Full Text] [Related]
6. PSA and prostate cancer screening: the challenge of the new millennium.
Bjartell A
Eur Urol; 2007 Nov; 52(5):1284-6. PubMed ID: 17720305
[No Abstract] [Full Text] [Related]
7. PSA screening: the bottom line.
Elhilali MM
CMAJ; 2000 Mar; 162(6):791-2. PubMed ID: 10750466
[No Abstract] [Full Text] [Related]
8. Comparison of different prostate-specific antigen cutpoints for early detection of prostate cancer: results of a large screening study.
Reissigl A; Pointner J; Horninger W; Ennemoser O; Strasser H; Klocker H; Bartsch G
Urology; 1995 Nov; 46(5):662-5. PubMed ID: 7495117
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
[TBL] [Abstract][Full Text] [Related]
10. Prostate specific antigen (PSA)-based screening.
Suzuki H; Flanigan RC; Okuyama A;
Int J Urol; 2008 Sep; 15(9):757-62. PubMed ID: 18786202
[No Abstract] [Full Text] [Related]
11. Prostate cancer screening.
Sikaris K
Pathology; 2012 Feb; 44(2):99-109. PubMed ID: 22198258
[TBL] [Abstract][Full Text] [Related]
12. Editorial comment: factor that influence serum prostate-specific antigen levels in terms of maintaining quality within a PSA screening system.
Ito K
Eur Urol; 2007 Sep; 52(3):714. PubMed ID: 17849514
[No Abstract] [Full Text] [Related]
13. [Multiparametric MRI for prostate cancer screening].
Hoeks CM; Fütterer JJ; Somford DM; van Oort IM; Huisman H; Barentsz JO
Ned Tijdschr Geneeskd; 2009; 153():B487. PubMed ID: 20003566
[TBL] [Abstract][Full Text] [Related]
14. Mass screening of 12,027 elderly men for prostate carcinoma by measuring serum prostate specific antigen.
Zhang HF; Wang HL; Xu N; Li SW; Ji GY; Li XM; Pan YZ; Zhang L; Zhao XJ; Gao HW
Chin Med J (Engl); 2004 Jan; 117(1):67-70. PubMed ID: 14733776
[TBL] [Abstract][Full Text] [Related]
15. The case for prostate cancer screening.
Andriole GL
Semin Urol; 1993 May; 11(2):50-3. PubMed ID: 7689738
[TBL] [Abstract][Full Text] [Related]
16. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population.
Bangma CH; Rietbergen JB; Kranse R; Blijenberg BG; Petterson K; Schröder FH
J Urol; 1997 Jun; 157(6):2191-6. PubMed ID: 9146612
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer: a review of common underwriting problems, Part 1.
Richie RC; Swanson JO
J Insur Med; 2004; 36(3):242-54. PubMed ID: 15495440
[TBL] [Abstract][Full Text] [Related]
18. [Free PSA: its routine use is premature in the screening of prostatic cancer].
Villers A; Chautard D
Prog Urol; 2000 Sep; 10(4):618-21. PubMed ID: 11064911
[TBL] [Abstract][Full Text] [Related]
19. Reliability of PSA testing remains unclear.
Ciatto S
BMJ; 2003 Sep; 327(7417):750. PubMed ID: 14512493
[No Abstract] [Full Text] [Related]
20. Weighing the benefits and downsides of prostate-specific antigen screening.
Pignone M
Arch Intern Med; 2009 Sep; 169(17):1554-6. PubMed ID: 19786672
[No Abstract] [Full Text] [Related]
[Next] [New Search]
